Zymeworks Inc (ZYME)

$23.93 -0.03 (-0.13%)
Market Cap 1.75B
Revenue (ttm) 105.97M
Net Income (ttm) -81.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 14.60
Profit Margin -76.56%
Debt to Equity Ratio 0.00
Volume 640,700
Avg Vol 666,176
Day's Range N/A - N/A
Shares Out 73.02M
Stochastic %K 12%
Beta 1.20
Analysts Strong Sell
Price Target $40.15

Company Profile

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-sp...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 274 8744
Address:
108 Patriot Drive, Suite A, Middletown, United States
StockMomentumLab
StockMomentumLab May. 15 at 3:34 PM
BIOTECH OPEN TAPE (5/15): mixed red/green across the sector as catalysts drive early volatility and rotation.- 1 👉Click to view @StockMomentumLab for timely updates amid the volatility. $ZYME -1% buyback announced $NRIX -1% new Bex data in urticaria $GILD -1% $3B notes pricing $BLTE -2% Retina China oral data $TNYA -2% TN-401 interim data beats sentiment High volatility, data-driven moves dominating biotech flow out of the gate
0 · Reply
briefingcom
briefingcom May. 15 at 12:32 PM
$ZYME: Zymeworks (+1.2%) announces its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $125.0 mln of its outstanding common stock, par value $0.00001 per share https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260514160823ZYME&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
NyseDayTrader
NyseDayTrader May. 14 at 11:17 PM
$ZYME
0 · Reply
maplelakeduckslayer
maplelakeduckslayer May. 14 at 9:52 PM
$ZYME $125 mil share repurchase program
0 · Reply
BuyingSheep
BuyingSheep May. 14 at 5:02 PM
$ZYME dead cat bounce already over? WHO would have guessed? 🤡
0 · Reply
Nickhzap
Nickhzap May. 11 at 5:57 PM
$ZYME perfect time for you to buy! But if you like losing money you can always try and short. Just trying to help
0 · Reply
BuyingSheep
BuyingSheep May. 11 at 6:34 AM
$ZYME the selloff continues PM. Only a 🤡 believes this could recover.
0 · Reply
BuyingSheep
BuyingSheep May. 10 at 6:40 AM
$ZYME https://x.com/mr_derivatives/status/2053348526940475520?s=46&t=aY8FhnMFrLc8t1_0WkvgLw Imagine how this turd 💩 will plummet once we see the bubble burst. 🥰 Generational wealth being made.
1 · Reply
MarketBeat
MarketBeat May. 9 at 9:06 AM
Zymeworks Q1 Earnings Call Highlights $ZYME https://www.marketbeat.com/instant-alerts/zymeworks-q1-earnings-call-highlights-2026-05-09/
0 · Reply
maplelakeduckslayer
maplelakeduckslayer May. 9 at 3:20 AM
$ZYME https://youtu.be/MucEHKrbfgA?si=EEGaGVvS_e2gRfbr
0 · Reply
Latest News on ZYME
Zymeworks authorizes share repurchase program of up to $125M

2026-05-14T22:14:23.000Z - 3 days ago

Zymeworks authorizes share repurchase program of up to $125M

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

May 14, 2026, 4:05 PM EDT - 3 days ago

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Zymeworks Announces Participation in Upcoming Investor Conferences

May 13, 2026, 6:00 AM EDT - 4 days ago

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks reports Q1 EPS (59c), consensus (10c)

2026-05-07T21:19:18.000Z - 10 days ago

Zymeworks reports Q1 EPS (59c), consensus (10c)

Zymeworks Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 10 days ago

Zymeworks Earnings Call Transcript: Q1 2026

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 4:05 PM EDT - 10 days ago

Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results

Zymeworks reports results from dose-escalation part of Phase 1 study for ZW191

2026-04-21T21:35:17.000Z - 26 days ago

Zymeworks reports results from dose-escalation part of Phase 1 study for ZW191

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Apr 21, 2026, 5:30 PM EDT - 26 days ago

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Zymeworks Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 21, 2026, 9:30 AM EDT - 26 days ago

Zymeworks Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Apr 17, 2026, 3:00 PM EDT - 4 weeks ago

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

Apr 16, 2026, 6:00 AM EDT - 4 weeks ago

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

Zymeworks Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 10:15 AM EDT - 4 weeks ago

Zymeworks Transcript: 25th Annual Needham Virtual Healthcare Conference

Zymeworks appoints new Head of R&D and Chief Business Officer

2026-04-09T10:11:05.000Z - 5 weeks ago

Zymeworks appoints new Head of R&D and Chief Business Officer

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

Apr 9, 2026, 6:00 AM EDT - 5 weeks ago

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

Zymeworks appoints Kristin Stafford as CFO

2026-04-01T10:06:59.000Z - 6 weeks ago

Zymeworks appoints Kristin Stafford as CFO

NVCR

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

Apr 1, 2026, 6:00 AM EDT - 6 weeks ago

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

Zymeworks receives FDA Fast Track Designation for ZW191

2026-03-30T10:06:54.000Z - 6 weeks ago

Zymeworks receives FDA Fast Track Designation for ZW191

Zymeworks announces Fast Track designation for ZW191 by FDA

2026-03-30T10:05:07.000Z - 6 weeks ago

Zymeworks announces Fast Track designation for ZW191 by FDA

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

Mar 30, 2026, 6:00 AM EDT - 6 weeks ago

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

Zymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting

2026-03-18T11:51:22.000Z - 2 months ago

Zymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting

JAZZ

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Mar 18, 2026, 7:46 AM EDT - 2 months ago

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Mar 17, 2026, 5:02 PM EDT - 2 months ago

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Zymeworks Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 10:10 AM EDT - 2 months ago

Zymeworks Transcript: The Citizens Life Sciences Conference 2026

Zymeworks Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 3:00 PM EDT - 2 months ago

Zymeworks Transcript: Leerink Global Healthcare Conference 2026

Zymeworks price target raised to $48 from $33 at Evercore ISI

2026-03-09T12:10:52.000Z - 2 months ago

Zymeworks price target raised to $48 from $33 at Evercore ISI

RPRX

Zymeworks price target raised to $46 from $32 at H.C. Wainwright

2026-03-06T11:22:16.000Z - 2 months ago

Zymeworks price target raised to $46 from $32 at H.C. Wainwright

Zymeworks price target raised to $47 from $40 at Stifel

2026-03-03T12:25:37.000Z - 2 months ago

Zymeworks price target raised to $47 from $40 at Stifel

Zymeworks Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 2:30 PM EST - 2 months ago

Zymeworks Transcript: TD Cowen 46th Annual Health Care Conference

Zymeworks Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:30 AM EST - 2 months ago

Zymeworks Earnings Call Transcript: Q4 2025

Zymeworks, Royalty Pharma enter $250M royalty-backed note financing

2026-03-02T11:15:10.000Z - 2 months ago

Zymeworks, Royalty Pharma enter $250M royalty-backed note financing

JAZZ ONC RPRX

Zymeworks reports Q4 EPS (55c) vs. (31c) last year

2026-03-02T11:10:50.000Z - 2 months ago

Zymeworks reports Q4 EPS (55c) vs. (31c) last year

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Mar 2, 2026, 6:01 AM EST - 2 months ago

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 6:00 AM EST - 2 months ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Feb 12, 2026, 6:00 AM EST - 3 months ago

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Zymeworks Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:00 PM EST - 4 months ago

Zymeworks Transcript: 44th Annual J.P. Morgan Healthcare Conference

Zymeworks announces executive changes

2026-01-12T11:31:44.000Z - 4 months ago

Zymeworks announces executive changes

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Jan 12, 2026, 6:00 AM EST - 4 months ago

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Zymeworks outlines priorities, outlook for 2026

2026-01-12T00:25:31.000Z - 4 months ago

Zymeworks outlines priorities, outlook for 2026

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Jan 11, 2026, 6:00 PM EST - 4 months ago

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Zymeworks touts ‘unprecedented’ results from HERIZON-GEA-01 trial

2026-01-06T18:45:54.000Z - 4 months ago

Zymeworks touts ‘unprecedented’ results from HERIZON-GEA-01 trial

JAZZ ONC

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Jan 6, 2026, 1:34 PM EST - 4 months ago

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Zymeworks Announces Participation in Upcoming Conferences

Dec 2, 2025, 4:05 PM EST - 5 months ago

Zymeworks Announces Participation in Upcoming Conferences

Zymeworks Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 10:00 AM EST - 5 months ago

Zymeworks Transcript: Evercore ISI 8th Annual HealthCONx Conference

Zymeworks Transcript: Investor Update

Nov 18, 2025, 8:30 AM EST - 6 months ago

Zymeworks Transcript: Investor Update

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Nov 18, 2025, 1:01 AM EST - 6 months ago

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Nov 18, 2025, 1:00 AM EST - 6 months ago

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

Nov 17, 2025, 8:10 AM EST - 6 months ago

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

JAZZ

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Nov 17, 2025, 6:00 AM EST - 6 months ago

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Zymeworks Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 6 months ago

Zymeworks Earnings Call Transcript: Q3 2025

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 6 months ago

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Zymeworks Transcript: Study Result

Oct 23, 2025, 3:30 PM EDT - 7 months ago

Zymeworks Transcript: Study Result

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Oct 23, 2025, 12:30 PM EDT - 7 months ago

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Oct 16, 2025, 6:00 AM EDT - 7 months ago

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Oct 13, 2025, 4:00 PM EDT - 7 months ago

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Oct 9, 2025, 8:30 AM EDT - 7 months ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

INM

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Oct 9, 2025, 6:00 AM EDT - 7 months ago

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Zymeworks Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 4:30 PM EDT - 9 months ago

Zymeworks Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Zymeworks halts development of cancer drug after trial setback

Sep 2, 2025, 6:18 AM EDT - 9 months ago

Zymeworks halts development of cancer drug after trial setback

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Sep 2, 2025, 6:00 AM EDT - 9 months ago

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Aug 11, 2025, 6:00 AM EDT - 9 months ago

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Zymeworks Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Zymeworks Earnings Call Transcript: Q2 2025

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 10 months ago

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Jul 28, 2025, 6:00 AM EDT - 10 months ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Jul 17, 2025, 6:00 AM EDT - 10 months ago

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Zymeworks Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 2:00 PM EDT - 1 year ago

Zymeworks Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

May 30, 2025, 6:00 AM EDT - 1 year ago

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

May 22, 2025, 5:00 PM EDT - 1 year ago

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

May 19, 2025, 4:15 PM EDT - 1 year ago

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Zymeworks Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Earnings Call Transcript: Q1 2025

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 1 year ago

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Apr 25, 2025, 1:00 PM EDT - 1 year ago

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Apr 21, 2025, 6:00 AM EDT - 1 year ago

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 17, 2025, 6:00 AM EDT - 1 year ago

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Zymeworks Earnings Call Transcript: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Zymeworks Earnings Call Transcript: Q4 2024

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 4:05 PM EST - 1 year ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Feb 26, 2025, 6:00 AM EST - 1 year ago

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Zymeworks Transcript: Citi's 2025 Virtual Oncology Leadership Summit

Feb 20, 2025, 2:00 PM EST - 1 year ago

Zymeworks Transcript: Citi's 2025 Virtual Oncology Leadership Summit

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Feb 18, 2025, 6:00 AM EST - 1 year ago

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Feb 13, 2025, 6:00 AM EST - 1 year ago

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Zymeworks Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 16, 2025, 11:15 AM EST - 1 year ago

Zymeworks Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Jan 8, 2025, 4:05 PM EST - 1 year ago

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Zymeworks Transcript: Status Update

Dec 12, 2024, 8:30 AM EST - 1 year ago

Zymeworks Transcript: Status Update

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Nov 21, 2024, 6:00 AM EST - 1 year ago

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

Nov 5, 2024, 6:00 AM EST - 1 year ago

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

Zymeworks Earnings Call Transcript: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Zymeworks Earnings Call Transcript: Q3 2024

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Oct 25, 2024, 6:00 AM EDT - 1 year ago

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

StockMomentumLab
StockMomentumLab May. 15 at 3:34 PM
BIOTECH OPEN TAPE (5/15): mixed red/green across the sector as catalysts drive early volatility and rotation.- 1 👉Click to view @StockMomentumLab for timely updates amid the volatility. $ZYME -1% buyback announced $NRIX -1% new Bex data in urticaria $GILD -1% $3B notes pricing $BLTE -2% Retina China oral data $TNYA -2% TN-401 interim data beats sentiment High volatility, data-driven moves dominating biotech flow out of the gate
0 · Reply
briefingcom
briefingcom May. 15 at 12:32 PM
$ZYME: Zymeworks (+1.2%) announces its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $125.0 mln of its outstanding common stock, par value $0.00001 per share https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260514160823ZYME&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
NyseDayTrader
NyseDayTrader May. 14 at 11:17 PM
$ZYME
0 · Reply
maplelakeduckslayer
maplelakeduckslayer May. 14 at 9:52 PM
$ZYME $125 mil share repurchase program
0 · Reply
BuyingSheep
BuyingSheep May. 14 at 5:02 PM
$ZYME dead cat bounce already over? WHO would have guessed? 🤡
0 · Reply
Nickhzap
Nickhzap May. 11 at 5:57 PM
$ZYME perfect time for you to buy! But if you like losing money you can always try and short. Just trying to help
0 · Reply
BuyingSheep
BuyingSheep May. 11 at 6:34 AM
$ZYME the selloff continues PM. Only a 🤡 believes this could recover.
0 · Reply
BuyingSheep
BuyingSheep May. 10 at 6:40 AM
$ZYME https://x.com/mr_derivatives/status/2053348526940475520?s=46&t=aY8FhnMFrLc8t1_0WkvgLw Imagine how this turd 💩 will plummet once we see the bubble burst. 🥰 Generational wealth being made.
1 · Reply
MarketBeat
MarketBeat May. 9 at 9:06 AM
Zymeworks Q1 Earnings Call Highlights $ZYME https://www.marketbeat.com/instant-alerts/zymeworks-q1-earnings-call-highlights-2026-05-09/
0 · Reply
maplelakeduckslayer
maplelakeduckslayer May. 9 at 3:20 AM
$ZYME https://youtu.be/MucEHKrbfgA?si=EEGaGVvS_e2gRfbr
0 · Reply
Tjcmd
Tjcmd May. 8 at 11:57 PM
$ZYME FYI…
2 · Reply
JFais
JFais May. 8 at 8:21 PM
$ZYME (NP) Interesting on today's gap down at $1.4B EV Repurchased 3.9M shares since Nov $403M of cash + $440M anticipated regulatory milestones = runway beyond 2028 Interesting optionality between BiC FRα & triumvirate of pan-RASi ADCs (PTK7, Ly6E and CLDN18.2 co-targets)
2 · Reply
BuyingSheep
BuyingSheep May. 8 at 7:35 PM
$ZYME misssed that one https://www.fiercebiotech.com/biotech/bms-calls-time-zymeworks-collab-ending-work-phase-1-stage-cancer-bispecific
1 · Reply
ScoobieDoo
ScoobieDoo May. 8 at 3:58 PM
$ZYME just averaged up to a lofty 11.75
1 · Reply
BuyingSheep
BuyingSheep May. 8 at 3:35 PM
$ZYME 🤡
0 · Reply
maplelakeduckslayer
maplelakeduckslayer May. 8 at 1:38 PM
$ZYME took some more on the gfs and mine roths...have a lot of cash available again after getting out of my BAND swing
0 · Reply
BuyingSheep
BuyingSheep May. 8 at 1:35 PM
$ZYME jeeez, what a dump 🤩💲💲💸💸
1 · Reply
StarshipBlooper
StarshipBlooper May. 8 at 12:04 AM
$ZYME the heck?
0 · Reply
BuyingSheep
BuyingSheep May. 7 at 8:25 PM
$ZYME Party on! 😂
1 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 7 at 8:21 PM
$ZYME Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.59 down -96.67% YoY • Reported revenue of $2.41M down -91.12% YoY • Zymeworks expects adjusted gross operating expenses (non-GAAP) in 2026 to be approximately 20% lower than the $170.5M reported in 2025, reflecting disciplined investment.
0 · Reply
BuyingSheep
BuyingSheep May. 7 at 4:02 PM
$ZYME the dump continues 🤡
0 · Reply
Boris_Badenov
Boris_Badenov May. 6 at 12:31 PM
$ZYME Jazz reported $13 million in Ziihera sales for 1Q26, little over 50% growth from previous quarter. Zyme jazz mgmt stated they’re ready to launch on approval for GEA. Data for the Phase 3 breastcancer study expected late 2027/early 2028. Early innings for Zyme’s revenue growth for this drug.
0 · Reply